![](https://scdn.x-mol.com/css/images/icon-new-link.png)
样式: 排序: IF: - GO 导出 标记为已读
-
A roadmap for clinical trials in MASH-related compensated cirrhosis Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-07-17 Juan M. Pericàs, Quentin M. Anstee, Salvador Augustin, Ramón Bataller, Annalisa Berzigotti, Andreea Ciudin, Sven Francque, Juan G. Abraldes, Virginia Hernández-Gea, Mònica Pons, Thomas Reiberger, Ian A. Rowe, Peter Rydqvist, Elmer Schabel, Frank Tacke, Emmanuel A. Tsochatzis, Joan Genescà
-
Disability inclusion in research and health care Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-07-15 Hannah Kuper, Tom Shakespeare
Globally, one in six people have a disability, and individuals with disabilities often experience a narrow margin of health, less financial security and health disparities. We call for action to improve access to health care for people with disabilities and show how this plan might be achieved.
-
Fgfbp1+ cells: upper crypt intestinal epithelial regeneration Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-07-11 Jordan Hindson
A new study published in Cell has identified a novel regenerative stem cell population in the upper crypt of the intestinal epithelium. The cells, which express Fgfbp1 and are distinct from Lgr5+ cells, were shown using time-resolved fate mapping and lineage tracing to give rise to Lgr5+ crypt base columnar cells and all other intestinal lineages — and continued to regenerate the intestinal epithelium
-
Neoadjuvant immunotherapy for mismatch repair-deficient colon cancer: a phase II study Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-07-11 Jordan Hindson
A multicentre phase II study (NICHE-2; NCT03026140) conducted by the Netherlands Cancer Institute has investigated the safety and efficacy of neoadjuvant immunotherapy in patients with locally advanced, mismatch repair-deficient colon cancer. Patients (n = 115 enrolled) were treated with neoadjuvant nivolumab (PD1 inhibitor) plus ipilimumab (CTLA4 inhibitor). After treatment, 113 patients (98%; 97
-
A bloody disgrace — time to change patient safety culture Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-07-08 Stuart Cantrill
After decades of institutional deceit, deflection, defensiveness and delay, publication of the final report of the Infected Blood Inquiry lays bare the failings of the British state and its National Health Service. Now, it is time for justice, accountability and a change in patient safety culture.
-
Incretin-based therapies for liver disease Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-07-08 Eleni Kotsiliti
The beginning of June saw the publication of four trials assessing the efficacy and safety of incretin-based drugs in steatotic liver disease and cirrhosis, coinciding with the European Association for the Study of the Liver 2024 Congress (5–8 June). In a phase II, dose-finding, multicentre, double-blind clinical trial (SYNERGY-NASH), Rohit Loomba and colleagues assessed the safety and efficacy of
-
ETS2 regulates human inflammatory macrophages in IBD Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-07-02 Katrina Ray
New research has identified ETS2 as a central regulator of human inflammatory macrophages. An intergenic region on chr21q22 (a so-called gene desert), which has been linked to a range of inflammatory disorders including inflammatory bowel disease (IBD), ankylosing spondylitis, primary sclerosing cholangitis and Takayasu arteritis, was investigated. A series of experiments pinpointed ETS2, an ETS-family
-
Digestive Disease Week 2024 Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-06-17 Katrina Ray
From 18–21 May 2024, Nature Reviews Gastroenterology & Hepatology was back at Digestive Disease Week (DDW) in Washington DC, USA, alongside >14,300 attendees both in person and virtually, according to the organizers. A wide array of sessions were available, covering basic, translational and clinical science in gastroenterology and hepatology. For basic and translational sciences, talks on the gut microbiome
-
Intermittent fasting for NASH and HCC in mice Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-06-14 Jordan Hindson
A recent study published in Cell Metabolism has investigated the effect of intermittent fasting on nonalcoholic steatohepatitis (NASH) and NASH-related hepatocellular carcinoma (HCC) in mice. First, the researchers demonstrated that Western diet-fed mice put on an intermittent fasting regimen (consisting of 2 non-consecutive days of fasting per week) were resistant to obesity and had significantly
-
Next generation of gastrointestinal electrophysiology devices Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-06-14 Haitao Liu, Siheng Sean You, Zhigang Gao, Ning Hu, Yunlong Zhao
-
Unlocking the promise of RAS inhibition in pancreatic cancer Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-06-14 Saurav D. Haldar, Nilofer S. Azad
-
Shaping new paths in clinical trial design to address alcohol use disorders and alcohol-associated liver disease Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-06-07 Juliana Serrazina, Helena Cortez-Pinto
-
Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-06-07 Brian P. Lee, Katie Witkiewitz, Jessica Mellinger, Frank A. Anania, Ramon Bataller, Thomas G. Cotter, Brenda Curtis, Srinivasan Dasarathy, Kelly S. DeMartini, Ivan Diamond, Nancy Diazgranados, Andrea F. DiMartini, Daniel E. Falk, Anne C. Fernandez, Margarita N. German, Patrick S. Kamath, Kelley M. Kidwell, Lorenzo Leggio, Raye Litten, Alexandre Louvet, Michael R. Lucey, Mary E. McCaul, Arun J. Sanyal
-
Envisioning how to advance the MASH field Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-06-04 Alina M. Allen, Zobair M. Younossi, Anna Mae Diehl, Michael R. Charlton, Jeffrey V. Lazarus
-
Endogenous ethanol production in health and disease Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-06-03 Abraham S. Meijnikman, Max Nieuwdorp, Bernd Schnabl
-
Hybrid APASL meeting 2024 Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-06-03 Eleni Kotsiliti
In March 2024, Nature Reviews Gastroenterology & Hepatology attended in person the 33rd annual meeting of the Asian Pacific Association for the Study of the Liver (APASL) in the historic city of Kyoto, Japan. In the opening ceremony, Masao Omata talked about hepatitis B virus (HBV) and hepatitis C (HCV) elimination and the need for a cirrhosis cure, and Shuichiro Shina (president of APASL 2024) addressed
-
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-06-03 Dominik Bettenworth, Mark E. Baker, Joel G. Fletcher, Vipul Jairath, Cathy Lu, Willem Bemelman, Geert d’Haens, Andre d’Hoore, Axel Dignass, Iris Dotan, Roger Feakins, Phillip Fleshner, Christina Ha, Gaylyn Henderson, Ruishen Lyu, Julian Panes, Gerhard Rogler, Ren Mao, Jordi Rimola, William J. Sandborn, Siew C. Ng, Britta Siegmund, Mark Silverberg, Stuart A. Taylor, Bram Verstockt, Ilyssa O. Gordon
-
Pride in gastroenterology and hepatology Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-05-31
For Pride Month, we celebrate the LGBTQ+ community and take stock of the challenges they continue to experience. Gastroenterologists and hepatologists can and should advocate, improve inclusion and be effective allies for our LGBTQ+ colleagues and patients.
-
Mechanisms of metastatic colorectal cancer Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-05-28 Adrià Cañellas-Socias, Elena Sancho, Eduard Batlle
-
Positive phase III trials for ileal bile acid transporter inhibitors Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-05-23 Katrina Ray
Two studies have reported positive phase III trials for ileal bile acid transporter inhibitors for pruritus and other cholestasis-associated clinical features. In the first study (ASSERT), the efficacy and safety of odevixibat was assessed for Alagille syndrome in a double-blind, randomized, placebo-controlled trial enrolling patients across ten countries. Patients (n = 52; median age 5.5 years) were
-
Sex and ethnic disparities persist in hepatitis B management Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-05-22 Katrina Ray
Real-world data on the use of nucleos(t)ide analogues (NAs) for chronic hepatitis B (CHB) are limited. A cross-sectional study within a retrospective multinational clinical consortium (2000–2021 REAL-B consortium) was examined to determine rates of CHB evaluation and treatment. Of 12,566 treatment-naive adults with CHB from 25 centres across 9 countries (mean age 47.1 years, 41.7% female patients,
-
A single-cell multiomics profile of Fontan-associated liver disease Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-05-21 Katrina Ray
The Fontan procedure is a reconstructive surgery for single-ventricle congenital heart disease. The procedure, often performed early in childhood, commonly results in multiple end-organ complications, including liver fibrosis or Fontan-associated liver disease (FALD). However, the underlying mechanisms of FALD are unknown and it is thought to be distinct from other forms of fibrotic liver disease.
-
Microbiota and colorectal cancer — controlling for confounders challenges associations Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-05-21 Katrina Ray
Controlling for confounders in quantitative microbiome data challenges the robustness of some reported associations between the gut microbiota and colorectal cancer (CRC) stages, according to a recent study. The faecal microbiota of 589 patients at different CRC stages was analysed and compared with up to 15 published studies (totalling 4,439 patients and controls). Quantitative microbiome profiling
-
Pleasurable and problematic receptive anal intercourse and diseases of the colon, rectum and anus Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-05-19 Daniel R. Dickstein, Collin R. Edwards, Catherine R. Rowan, Bella Avanessian, Barbara M. Chubak, Christopher W. Wheldon, Priya K. Simoes, Michael H. Buckstein, Laurie A. Keefer, Joshua D. Safer, Keith Sigel, Karyn A. Goodman, B. R. Simon Rosser, Stephen E. Goldstone, Serre-Yu Wong, Deborah C. Marshall
-
Development of MKK4 inhibitors for liver regeneration Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-05-15 Jordan Hindson
The kinase MKK4 is a regulator of hepatocyte regeneration. A new study published in Cell reports the development of small-molecule inhibitors of MKK4. HRX215 increased liver regeneration post-hepatectomy in mouse and pig models and increased hepatocyte proliferation in fibrotic mouse livers post-partial hepatectomy. In addition, HRX215 treatment prevented post-hepatectomy liver failure in a lethal
-
Telemedicine for hepatitis C virus treatment in opioid treatment programmes Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-05-15 Jordan Hindson
A prospective randomized clinical trial (NCT02933970) has compared the efficacy of hepatitis C virus infection treatment via facilitated telemedicine integrated into opioid treatment programmes (n = 290) versus standard-of-care off-site hepatitis specialist referral (n = 312). The study was conducted across opioid treatment programmes in New York, USA. In the telemedicine group, 92.4% of patients initiated
-
Rhythmicity of infant microbiota and dietary effects Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-05-14 Jordan Hindson
A new study published in Cell Host & Microbe has compared the development of the microbiota in breast-fed and formula-fed infants. In the trial, 210 infants were randomly assigned to be breast-fed or to receive one of four formulas containing varying supplements, such as bifidobacteria or galacto-oligosaccharides, during the first year of life. The researchers found similar faecal bacterial communities
-
Multi-omic links between gut microbiome and cardiovascular disease Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-05-14 Jordan Hindson
The Framingham Heart Study is an ongoing observational cohort study to identify risk factors for cardiovascular disease. Xavier and colleagues used data from study participants to investigate links between the gut microbiome and cardiovascular disease. They generated stool metagenomic and metabolomic data from 1,429 study participants. In particular, they identified that Oscillibacter species were
-
Mitochondrial function and gastrointestinal diseases Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-05-13 Parsa S. Haque, Neeraj Kapur, Terrence A. Barrett, Arianne L. Theiss
-
Transgender health care in the United States: legal, ethical and practical concerns for gastroenterologists in a changing landscape Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-05-01 Sarah Singh, Nikki Duong, Laura Targownik, Sonali Paul, Christopher Vélez, Lauren D. Feld
-
Pouchitis: pathophysiology and management Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-04-25 Bo Shen
-
Spatial genomics: mapping human steatotic liver disease Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-04-23 Kylie P. Matchett, Jasmin Paris, Sarah A. Teichmann, Neil C. Henderson
-
A crucial Fusobacterium nucleatum clade in colorectal cancer Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-04-16 Katrina Ray
A distinct Fusobacterium nucleatum clade, Fna C2, that is dominant in the human colorectal cancer (CRC) niche has been identified in a new study published in Nature. Importantly, in mice, Fna C2 treatment led to increased numbers of large intestinal adenomas and altered metabolite profiles. The findings illuminate the crucial connection between a bacterial subspecies and human colon cancer and provide
-
Artificial intelligence in liver cancer — new tools for research and patient management Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-04-16 Julien Calderaro, Laura Žigutytė, Daniel Truhn, Ariel Jaffe, Jakob Nikolas Kather
-
Promoting allyship to support and uplift the LGBTQIA+ community Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-04-05 Daniel J. Huynh, Sonali Paul, Nikki Duong
The lesbian, gay, bisexual, transgender, queer, intersex and asexual (LGBTQIA+) community navigates a complex social landscape marked by strides in acceptance alongside enduring discrimination. Allies — individuals outside of the LGBTQIA+ spectrum who support and advocate for this community — are paramount, with allyship playing a critical part in influencing the health and well-being of LGBTQIA+ individuals
-
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-04-04 Ipsita Mohanty, Celeste Allaband, Helena Mannochio-Russo, Yasin El Abiead, Lee R. Hagey, Rob Knight, Pieter C. Dorrestein
Bile acids regulate nutrient absorption and mitochondrial function, they establish and maintain gut microbial community composition and mediate inflammation, and they serve as signalling molecules that regulate appetite and energy homeostasis. The observation that there are hundreds of bile acids, especially many amidated bile acids, necessitates a revision of many of the classical descriptions of
-
New understanding of hepatobiliary MRI Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-04-02 Catherine M. Pastor, Valérie Vilgrain
Magnetic resonance imaging following injection of hepatobiliary contrast agents improves the detection of hepatocellular carcinomas when contrast agent accumulations in tumours and the surrounding pathological liver differ. However, tissue accumulation is poorly investigated, and this Clinical Outlook article highlights experimental data to understand better contrast agent accumulation in human pathological
-
Improving culturally safe engagement with sexual and gender minority populations Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-04-02 Newsha Nikzad, Nikki Duong, Sonali Paul
Cultural safety seeks to remediate health inequities through empowering marginalized and minoritized patient populations, minimizing implicit bias and incorporating social determinants of health into practice. Here, we propose a cultural safety framework to guide communication with patients from sexual and gender minorities.
-
Tackling sorbitol intolerance Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-03-25 Maria Papatriantafyllou
Sorbitol, a poorly absorbable sweetener, is catabolized by gut microbiota, mainly Clostridia. Lee et al. now elucidate the pathophysiology of sorbitol intolerance and highlight a role for Clostridia and butyrate, a short-chain fatty acid metabolite. Stable engraftment of Escherichia coli strain Nissle 1917, a probiotic that catabolizes sorbitol, restored caecal SDH activity in mice and protected them
-
Seladelpar in primary biliary cholangitis Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-03-22 Eleni Kotsiliti
In a phase III, double-blind, placebo-controlled trial, 193 patients with primary biliary cholangitis and an inadequate response to or a history of unacceptable side effects with ursodeoxycholic acid were randomly assigned in a 2:1 ratio to receive daily 10 mg oral seladelpar (a PPARδ agonist) or placebo. The primary endpoint was set at month 12 as a biochemical response defined as an alkaline phosphatase
-
HCC genomic landscape in Chinese individuals Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-03-22 Eleni Kotsiliti
Researchers from the Chinese Liver Cancer Atlas project performed deep whole-genome sequencing of hepatocellular carcinoma (HCC) tumours from 494 Chinese individuals (86.4% men and 13.6% women) who received no preoperative anti-cancer treatment. According to epidemiological data, 94.5% of the enrolled patients had hepatitis B, 2.6% had hepatitis C, 26.7% drank alcohol and 36.8% smoked. The researchers
-
Bacteriophages and host inflammation in IBD Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-03-22 Eleni Kotsiliti
Researchers analysed metagenomic data from 1,618 patients with inflammatory bowel disease (IBD) and 791 healthy individuals as controls and identified invertible DNA orientations in Bacteroidales genomes. Of those 311 invertible regions, 147 were markedly different in terms of orientation in patients with IBD. The inverted regions included, among others, the anti-inflammatory PSA promoter of Bacteroides
-
Biomarker shows no clinical use in guiding treatment for Crohn’s disease Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-03-22 Eleni Kotsiliti
Between 29 December 2017 and 5 January 2022, in a multicentre, open-label, biomarker-stratified, interventional clinical trial (PROFILE), 386 adult patients with newly diagnosed active Crohn’s disease were randomly assigned to two groups: top-down (early combined immunosuppression with infliximab (a TNF monoclonal antibody) and an immunomodulator) or accelerated step-up (conventional) treatment. The
-
Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-03-18 Yasser Fouad, Salma Barakat, Almoutaz Hashim, Hasmik Ghazinyan
Fatty liver disease is one of the most common liver diseases in the Middle East and North Africa region, and globally. Unfortunately, there is a lack of awareness regarding this condition. The nomenclature changes for NAFLD (to MAFLD or MASLD) have gained considerable attention in the hepatology community. Here, we present our point of view on this ongoing change and debate.
-
Future direction of total neoadjuvant therapy for locally advanced rectal cancer Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-03-14 Yoshinori Kagawa, J. Joshua Smith, Emmanouil Fokas, Jun Watanabe, Andrea Cercek, Florian R. Greten, Hideaki Bando, Qian Shi, Julio Garcia-Aguilar, Paul B. Romesser, Natally Horvat, Hanna Sanoff, William Hall, Takeshi Kato, Claus Rödel, Arvind Dasari, Takayuki Yoshino
-
Cell senescence in liver diseases: pathological mechanism and theranostic opportunity Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-03-14 David Sanfeliu-Redondo, Albert Gibert-Ramos, Jordi Gracia-Sancho
-
ECCO’24 Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-03-13 Katrina Ray
In February 2024, Nature Reviews Gastroenterology & Hepatology attended the 19th Congress of ECCO (ECCO’24) in Stockholm, Sweden. The meeting, according to the organizers, had >7,200 participants (represented by 99 countries) and focused on inflammatory bowel disease (IBD), with this year’s congress theme being ‘Crossing Borders in IBD’. The ‘crossing borders’ theme tied well with the new REACH strategy
-
Screening for liver fibrosis: lessons from colorectal and lung cancer screening Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-03-13 Maja Thiele, Patrick S. Kamath, Isabel Graupera, Antoni Castells, Harry J. de Koning, Miquel Serra-Burriel, Frank Lammert, Pere Ginès
-
Group 3 innate lymphoid cells in intestinal health and disease Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-03-11 Veronika Horn, Gregory F. Sonnenberg
-
2023 FDA approvals in gastroenterology and hepatology Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-03-07 Eleni Kotsiliti
In 2023, the Center for Drug Evaluation and Research (CDER) of the US Food and Drug Administration (FDA) approved 55 novel drugs, 4 related to gastroenterology and hepatology. In 2022, the new drug approvals included treatments for Helicobacter pylori infection, T2DM blood sugar control in addition to diet and exercise, FGFR2-aberrant intrahepatic cholangiocarcinoma and unresectable hepatocellular
-
Ultra-processed foods and food additives in gut health and disease Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-02-22 Kevin Whelan, Aaron S. Bancil, James O. Lindsay, Benoit Chassaing
-
Another renaissance for bile acid gastrointestinal microbiology Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-02-21 Jason M. Ridlon, H. Rex Gaskins
-
Resmetirom proves positive for NASH with liver fibrosis Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-02-15 Katrina Ray
Positive phase III results have been reported for resmetirom (a thyroid hormone receptor β-selective agonist) for the treatment of nonalcoholic steatohepatitis (NASH; also known as metabolic dysfunction-associated steatohepatitis (MASH)) with liver fibrosis. In a phase III, randomized controlled trial, 966 patients with biopsy-confirmed NASH and liver fibrosis (stage F1B, F2 or F3) were randomly assigned
-
A gut–liver axis in intestinal stem cell fitness Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-02-14 Katrina Ray
New research demonstrates that the gut–liver axis plays a part in calibrating intestinal stem cell (ISC) expansion during intestinal homeostasis in mice, with a key role for the hepatokine pigment epithelium-derived factor (PEDF). In a series of experiments using transcriptomics, proteomics and hepatectomy in mouse models, the researchers identified PEDF, a liver-derived soluble WNT inhibitor, which
-
Gastrointestinal and brain barriers: unlocking gates of communication across the microbiota–gut–brain axis Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-02-14 María R. Aburto, John F. Cryan
-
Sugemalimab with chemotherapy for advanced ESCC Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-02-14 Katrina Ray
A multicentre, randomized, double-blind, phase III trial reported positive results for sugemalimab (a PDL1 antibody) plus chemotherapy for the treatment of advanced oesophageal squamous cell carcinoma (ESCC). A total of 540 adults (aged 18–75 years) with unresectable, locally advanced, recurrent or metastatic ESCC who had not received prior systemic treatment were randomly assigned 2:1 to receive either
-
GLP1 agonists and risk of major adverse liver outcomes Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-02-14 Katrina Ray
Glucagon-like peptide 1 (GLP1) agonists could be a treatment option to reduce risk of major adverse liver outcomes (MALO) in patients with type 2 diabetes mellitus (T2DM) and any chronic liver disease (CLD) who adhere to treatment over time, according to estimates using modelling of observational data to emulate a target trial of GLP1 agonists in this population. Observational data from Swedish health-care
-
Live bacterial therapeutics for detection and treatment of colorectal cancer Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-02-14 Joanna Zhang, Jeff Hasty, Amir Zarrinpar
-
HCV direct-acting antiviral therapy adherence in people who inject drugs Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-02-12 Jordan Hindson
A new study (HERO) published in the Journal of Hepatology has investigated the association between direct-acting antiviral treatment adherence and sustained virological response (SVR) in patients with hepatitis C virus (HCV) infection and who inject drugs. Over a 12-week treatment period, electronic blister packs assessed adherence to sofosbuvir with velpatasvir in people who inject drugs (n = 623
-
Linaclotide for functional constipation in paediatric patients: phase III results Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-02-12 Jordan Hindson
Linaclotide is a guanylate cyclase C agonist used for the treatment of chronic idiopathic constipation in adults. A randomized, multicentre phase III trial assessed use of linaclotide in paediatric patients with functional constipation. 330 patients (6–17 years of age) were randomly assigned to receive oral linaclotide (72 μg) or placebo once per day for a 12-week period. Patients in the linaclotide